GlassScriptPhysician profile
Renee Drew
NPI 1972724995
$1,622.96
in general payments reported to CMS, 2019-2025
19 companies · $699 in 2025
The $699 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.08 · 2022: $43.38 · 2023: $138 · 2024: $722 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,558.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $265.70 | 2024-2025 | |
| Janssen Biotech, INC. | $235.12 | 2024-2025 | Tecvayli, Rybrevant, Talvey |
| Pfizer INC. | $164.16 | 2023-2024 | |
| Stemline Therapeutics INC. | $150.23 | 2024 | Orserdu |
| Novartis Pharmaceuticals Corporation | $133.03 | 2024-2025 | |
| Daiichi Sankyo INC. | $108.20 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.63 | 2025 | |
| Abbvie INC. | $75.18 | 2025 | |
| Merck Sharp & Dohme LLC | $62.34 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Ipsen Biopharmaceuticals, INC | $56.49 | 2024 | Onivyde |
| Incyte Corporation | $51.73 | 2025 | |
| Gilead Sciences, INC. | $46.99 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.89 | 2024 | |
| Jazz Pharmaceuticals INC. | $31.78 | 2024 | |
| Tersera Therapeutics LLC | $27.63 | 2025 | Xermelo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $24.97 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $22.99 | 2025 | Opdivo |
| G1 Therapeutics, INC. | $20.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $18.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Drew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.